PIRFENIDONE AND PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)

吡非尼酮和特发性肺纤维化 (IPF) 患者

• 批准号: 7950773
• 负责人: MARK Louis BRANTLY
• 金额: $ 0.08万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950773
• 关键词: Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dose; Eligibility Determination; Funding; Geographic Locations; Grant; Hamman-Rich syndrome; Institution; Patients; Pirfenidone; Protocols documentation; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Visit; follow-up; meetings; open label; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open-label, multicenter, extension study for patients with idiopathic pulmonary fibrosis-IPF who complete the CAPACITY Trials, either PIPF-004 or PIPF-006. Eligible patients must complete the Final Follow-Up Visit for the CAPACITY studies and meet all of the eligibility criteria noted in this protocol. The duration of treatment for each patient will be variable and will continue until pirfenidone is commercially available in a geographic region, the study is terminated by the sponsor for reasons outlined in Section 3.9 of the sponsor?s protocol, or approximately 2.5 years have elapsed since the patient?s first dose of pirfenidone, whichever is shortest.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项在完成CAPACITY试验（PIPF-004或PIPF-006）的特发性肺纤维化-IPF患者中进行的开放标签、多中心、扩展研究。 合格患者必须完成CAPACITY研究的最终随访访视，并符合本方案中规定的所有合格性标准。 每例患者的治疗持续时间将是可变的，并将持续至吡非尼酮在某个地理区域上市，申办者出于申办者？的协议，或大约2.5年过去了，因为病人？吡非尼酮首次给药，以时间最短者为准。